CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 279 enrolled
Drug / intervention
Atorvastatin +1 moredrug
Likely dose
Atorvastatin 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01988571
NCT01988571Phase 2Completed
CompareCT.gov

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

Wake Forest University Health Sciences·interventional·Posted Nov 20, 2013·Updated Jan 4, 2022

In Brief

A Phase 2 clinical trial evaluating Atorvastatin and Placebo for Breast Cancer and Lymphoma. Completed, enrolled 279 participants across 51 sites.

Detailed Summary

The purpose of this research study is to see if Atorvastatin (Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in individuals receiving adjuvant anthracycline-based chemotherapy for breast cancer of lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 20, 2013
Enrollment StartFeb 1, 2014
Primary CompletionSep 24, 2020
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 12.6 years ago

Interventions

Atorvastatindrug

40 mg tablet taken by mouth each morning for 24 months.

Placebodrug

One placebo tablet taken each morning orally for 24 months.